FWP - フォワ―ド・ファ―マ (Forward Pharma A/S) フォワ―ド・ファ―マ

 FWPのチャート


 FWPの企業情報

symbol FWP
会社名 Forward Pharma A/S (フォワ―ド・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187 a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications including multiple sclerosis (MS). The Company's clinical candidate FP187 is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders such as psoriasis. The Company's DMF formulation FP187 employs over two methods which improves the release of DMF by reducing the peaks of monomethyl fumarate (MMF) in the bloodstream while maintaining overall DMF exposure levels which in turn controls DMF's side effects. The Company has conducted a pre-clinical program and has completed several Phase I and Phase II clinical trials for the product FP187.   フォワ―ド・ファ―マはデンマ―クのバイオ医薬品会社。多発性硬化症及び乾癬などの免疫疾患の治療法を開発・商品化する。免疫調節化合物のフマル酸ジメチルや誘導体に重点を置いた、遅延・持続放出性の経口医薬品の開発活動を行う。同社は2005年に設立され、コペンハ―ゲンに拠点を置く。  Forward Pharma A/S is a biopharmaceutical company, which engages in the research and development of medicinal treatment for inflammatory and neurological indications. It focuses on the immunomodulatory compound dimethyl fumarate and its derivatives. The company was founded by Florian Schönharting on July 1, 2005 and is headquartered in Copenhagen, Denmark.
本社所在地 Ostergrade 24A 1 Copenhagen DK-1100 DNK
代表者氏名 Claus Bo Svendsen Claus Bo Svendsen
代表者役職名 Chief Executive Officer
電話番号 -7543
設立年月日 38534
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 5人
url www.forward-pharma.com
nasdaq_url https://www.nasdaq.com/symbol/fwp
adr_tso 11484285
EBITDA EBITDA(百万ドル) -33.82800
終値(lastsale) 2.44
時価総額(marketcap) 28021655.4
時価総額 時価総額(百万ドル) 100.03010
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 10.76910
当期純利益 当期純利益(百万ドル) -29.41300
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Forward Pharma A/S revenues decreased from $1.25B to $0K. Net loss totaled $5.3M vs. income of $941.2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Net loss reflects General and Administrative costs increase of 31% to $5.8M (expense) Interest Income decrease from $160K (income) to $0K.

 FWPのテクニカル分析


 FWPのニュース

   Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares  2019/11/26 21:05:00 GlobeNewswire
COPENHAGEN, Denmark, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that its Board of…
   Forward Pharma reports FY results  2019/04/04 20:36:54 Seeking Alpha
   Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares  2019/11/26 21:05:00 GlobeNewswire
COPENHAGEN, Denmark, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that its Board of…
   Forward Pharma reports FY results  2019/04/04 20:36:54 Seeking Alpha
   Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares  2019/11/26 21:05:00 GlobeNewswire
COPENHAGEN, Denmark, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”) today announced that its Board of…
   Forward Pharma reports FY results  2019/04/04 20:36:54 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 フォワ―ド・ファ―マ FWP Forward Pharma A/S)

 twitter  (公式ツイッターやCEOツイッターなど)